logo

For the Inventor, By the Inventor

Rockville, MD, United States of America

Rexahn Pharmaceuticals, Inc.


USPTO Granted Patents = 19



Forward Citations = 39

Loading Chart...
Loading Chart...

26 inventors (with patents filed for the assignee):

goldMedal Young Bok Lee (16 out of 20 patents)

silverMedal Deog Joong Kim (13 out of 15 patents)

bronzeMedal Chang Ho Ahn (7 out of 11 patents)

4.  Chang-Ho Ahn (5 out of 6 patents)

5.  Reza Mazhari (4 out of 8 patents)

6.  Yi Wang (3 out of 7 patents)

7.  Haifeng Yin (3 out of 3 patents)

8.  Eliezer Falb (3 out of 4 patents)

9.  Leigh Andre Pearcey (3 out of 3 patents)

10.  Jonathan Cummins (3 out of 4 patents)

11.  Petra Dieterich (3 out of 6 patents)

12.  Jean-Francois Carniaux (3 out of 5 patents)

13.  Vikram Chandrakant Purohit (3 out of 3 patents)

14.  Daniel Edward Emrich (2 out of 2 patents)

15.  Godefridus J Peters (2 out of 2 patents)


19 patents:

1. 10570101 - Quinoxalinyl-piperazinamide methods of use (2020-02-25),
2. 10278971 - Fluorocyclopentenylcytosine methods of use (2019-05-07),
3. 10052321 - Nanoparticulate compositions and formulations of piperazine compounds (2018-08-21),
4. 9969698 - Quinoxalinyl-piperazinamide methods of use (2018-05-15),
5. 9920016 - Process for the preparation of 4-amino 1-((1S,4R,5S)-2-fluoro-4,5-dihydroxy-3-hydroxymethyl-cyclopent-2-enyl)-1H-pyrimidin-2-one (2018-03-20),
6. 9782410 - Fluorocyclopentenylcytosine methods of use (2017-10-10),
7. 9744167 - Nanoparticulate compositions and formulations of piperazine compounds (2017-08-29),
8. 9713615 - Tetrahydroisoquinolin-2-yl-(quinazolin-4-yl)methanone compounds (2017-07-25),
9. 9533958 - Process or the preparation of 4-amino 1-((1S,4R,5S)-2-fluoro-4,5-dihydroxy-3-hydroxymethyl-cyclopent-2-Enyl)-1H-pyrimidin-2-one (2017-01-03),
10. 9434610 - HPMA—docetaxel conjugates and uses therefore (2016-09-06),
11. 9193707 - Tetrahydroisoquinolin-2-yl-(quinazolin-4-yl)methanone compounds (2015-11-24),
12. 9150520 - Process for the preparation of 4-amino-1-((1S,4R,5S)-2-fluoro-4,5-dihydroxy-3-hydroxymethyl-cyclopent-2-enyl)-1H-pyrimidin-2-one (2015-10-06),
13. 8846110 - Polymeric systems for the delivery of anticancer drugs (2014-09-30),
14. 8598173 - 1-[(6,7-substituted alkoxyquinoxalinyl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives for treating tumors (2013-12-03),
15. 8404698 - Quinazoline derivatives and therapeutic use thereof (2013-03-26),
Rexahn Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative cancer treatments. With a mission to improve the lives of cancer patients, Rexahn specializes in developing targeted therapies that inhibit specific pathways involved in tumor growth and progression. Through its proprietary technology platforms, the company aims to deliver next-generation therapies that provide better outcomes and fewer side effects. For more information, please visit the website.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

19 Patents

#33 in Rockville, MD

#220 in Maryland

#16,629 in US

#31,713 in the World

...
Rockville, MD, United States of America

Rexahn Pharmaceuticals, Inc.

Forward Citations = 39

26 inventors:

goldMedal Young Bok Lee (16 out of 20 patents)

silverMedal Deog Joong Kim (13 out of 15 patents)

bronzeMedal Chang Ho Ahn (7 out of 11 patents)

4.  Chang-Ho Ahn (5 out of 6 patents)

5.  Reza Mazhari (4 out of 8 patents)

Please report any incorrect information to support@idiyas.com
Loading…